Idiopathic Pulmonary Fibrosis

• 

  Subject Areas on Research

  • 129Xenon Gas Exchange Magnetic Resonance Imaging as a Potential Prognostic Marker for Progression of Idiopathic Pulmonary Fibrosis. 
  • A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. 
  • A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. 
  • A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. 
  • A protocol for quantifying cardiogenic oscillations in dynamic 129 Xe gas exchange spectroscopy: The effects of idiopathic pulmonary fibrosis. 
  • A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. 
  • A simplified technique for pulmonary artery aneurysm repair in a lung transplant recipient with right ventricular outflow tract obstruction. 
  • Advances in Interstitial Lung Disease Genetics. 
  • An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. 
  • Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. 
  • Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. 
  • Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. 
  • Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease? 
  • Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. 
  • Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. 
  • Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. 
  • Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. 
  • Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. 
  • Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. 
  • Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together? 
  • Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates. 
  • Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. 
  • Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. 
  • Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. 
  • Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. 
  • Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. 
  • Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. 
  • Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. 
  • Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. 
  • Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. 
  • Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis. 
  • Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. 
  • Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. 
  • Esophageal Dysmotility, Gastro-esophageal Reflux Disease, and Lung Transplantation: What Is the Evidence? 
  • Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. 
  • Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. 
  • Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. 
  • Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry. 
  • Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. 
  • Hospitalizations in patients with idiopathic pulmonary fibrosis. 
  • Hyperpolarized 129 Xe gas transfer MRI: the transition from 1.5T to 3T. 
  • Hypoxic Gene Expression of Donor Bronchi Linked to Airway Complications after Lung Transplantation. 
  • Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. 
  • Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. 
  • Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres. 
  • Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. 
  • In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study. 
  • Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. 
  • Interleukin-13 disrupts type 2 pneumocyte stem cell activity. 
  • LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. 
  • Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. 
  • Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. 
  • Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. 
  • Management of Idiopathic Pulmonary Fibrosis. 
  • Mapping cardiopulmonary dynamics within the microvasculature of the lungs using dissolved 129Xe MRI. 
  • Multicentric reticulohistiocytosis: a unique case with pulmonary fibrosis. 
  • New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. 
  • Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. 
  • Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). 
  • Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. 
  • Pulmonary dysfunction after lung transplantation: the dilemma of coexisting mitral regurgitation. 
  • Pulmonary fibrosis: patterns and perpetrators. 
  • Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. 
  • Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. 
  • Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. 
  • Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. 
  • Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. 
  • Removal of Epithelialized Uncovered Metal Stent. A New Approach to An Old Problem. 
  • Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. 
  • Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia. 
  • Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. 
  • Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. 
  • Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. 
  • Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. 
  • TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. 
  • Telomere length in patients with unclassifiable interstitial lung disease: a cohort study. 
  • That Was Then, This Is Now: A Fresh Look at Idiopathic Pulmonary Fibrosis Biomarkers in the Antifibrotic Era. 
  • The IPFnet Strategy: Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. 
  • The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. 
  • The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. 
  • The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. 
  • The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. 
  • Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. 
  • Transverse relaxation rates of pulmonary dissolved-phase Hyperpolarized 129 Xe as a biomarker of lung injury in idiopathic pulmonary fibrosis. 
  • Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. 
  • Uncovering a third dissolved-phase 129 Xe resonance in the human lung: Quantifying spectroscopic features in healthy subjects and patients with idiopathic pulmonary fibrosis. 
  • Uncovering the Epidemiology of Idiopathic Pulmonary Fibrosis in the Veterans Affairs Health System. 
  • Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. 
  • Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. 
  • What Is the Optimal Transplant for Older Patients With Idiopathic Pulmonary Fibrosis? 
  • Workshop on idiopathic pulmonary fibrosis in older adults. 
  • ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation. 
  • β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix.